Biotalys Reports Full-Year 2025 Financial Results and Business Highlights
Biotalys, an Agricultural Technology company, announced its 2025 financial results and business highlights, including the U.S. EPA approval of its biofungicide EVOCA. The company has streamlined its leadership and operations to focus on commercializing EVOCA NG and BioFun-6.
Biotalys, an Agricultural Technology (AgTech) company, announced its 2025 financial results and business highlights. The company received final approval from the U.S. EPA for its biofungicide EVOCA and a positive recommendation from the Dutch regulator. Biotalys has €8.0 million in cash and cash equivalents, providing a financial runway until May 2026. The company is streamlining its operations to focus on commercializing EVOCA NG and BioFun-6. Biotalys has suspended early-stage activities to reduce operating expenses while safeguarding its technology platform. The company will prioritize the development and regulatory advancement of its lead biofungicide assets.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.